Topical sirolimus gel Hyftor has received marketing authorisation in the UK for TSC facial angiofibromas (growths and marks on the skin from TSC). This means UK decision-makers confirm that Hyftor has met their standards for safety, quality and benefit. Hyftor is a gel that
We caught up with TSC researcher Liezl Schlebusch about the importance of carer wellbeing and her upcoming TSA-funded study, Well-Beans for Caregivers. Liezl is a lecturer based at the Centre for Autism Research in Africa at University of Cape Town. There is a saying:
As part of our work to highlight Global TSC Awareness Day and Global Mental Health Awareness Week, both of which started on 15 May, we asked the TSC community to share their experiences of TSC and mental health challenges. Rebecca, who is aged 24
The TSA is delighted to be partnering with Epilepsy Research UK to co-fund new, vital research into TSC-related epilepsy through the Fellowship Award. After a rigorous process of reviewing applications, we can now announce that Dr Amanda Almacellas Barbanoj has been chosen for the
Children aged between 6 months – four years old in England are to be offered a covid-19 booster vaccine this spring, if they are considered clinically vulnerable to the virus The news follows the recommendation from the UK Government’s Joint Committee on Vaccination and
Lucy Wilde, from the Cerebra Centre for Neurodevelopmental Disorders in the School of Psychology, has been awarded one of the first postdoctoral research training fellowships from the UK support group charity the Tuberous Sclerosis Association. The research, which will be based at the Cerebra Centre
We still have 5 places available for this run Why not take part, get fit, have fun and support us at the same time. The British 10k London Run 8th July 2012 More Details Here Contact Janet Brewer for entry forms.
The Challenging Behaviour Foundation has produced new summary information sheets about challenging behaviour. Their information sheets are written by experts and cover a wide range of topics connected to challenging behaviour and severe learning disabilities. They are written for both family carers and professionals. The
The Challenging Behaviour Foundation has produced three new ‘At a glance’ guides aimed at family carers supporting people whose behaviour is described as challenging. There are separate guides for adults, teenagers and children. The guides have been developed in collaboration with the Social Care Institute
Everolimus granted European Licence for renal AML Everolimus (trade name Votubia®) has been approved by the regulators for use in the European Union for the treatment of angiomyolipomata (AMLs) in adults with TSC, when embolisation or surgery is not immediately needed. Everolimus belongs to a
